Key Findings:  Resulting data suggest that pharmacological treatments with CB2 agonists (i.e. HU-308) may represent a novel treatment strategy in PD patients suffering from L-dopa induced dyskinesia (a relatively common and debilitating side-effect of the drug).
Type of Study:  Animal Study
Study Result:  Positive
Cannabinoids Studied:  HU-x Synthetic Cannabinoids
Phytocannabinoid Source:  Not Applicable